Advertisement

Topics

Arrakis Therapeutics Company Profile

10:43 EDT 18th June 2019 | BioPortfolio

Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. The company’s TRYST™ and PEARL-seq™ platforms identify new RNA targets and drug candidates to treat diseases unaddressed by today’s medicines. Arrakis is developing a proprietary pipeline of RNA-targeted small molecules focused on neurologic diseases, cancer, and rare genetic diseases.


News Articles [865 Associated News Articles listed on BioPortfolio]

Arrakis Therapeutics Nabs $75 Million to Create a New Class of rSM Oncology Drugs

The funding will allow Arrakis to realize its vision of creating a new class of medicines with RNA-targeted small molecules, or rSMs.

Former Sigilion Exec Paul Wotton Named Obsidian Therapeutics CEO

Obsidian Therapeutics has appointed Paul Wotton to serve as its new CEO. Wotton succeeds CEO Michael Gilman, who had been splitting his time between Obsidian and Arrakis Therapeutics. Gilman is now CE...

Funding round raises $75M for Arrakis

A round of Series B funding has pulled in $75 million for Arrakis Therapeutics, which recently launched one program for a car -More- 

It’s Tough to Find Drugs to Bind to RNA: Arrakis Nabs $75M to Help

Arrakis Therapeutics has been scouting elusive pharmaceutical quarry: small molecules able to “drug” RNA, the molecular messengers that carry the genetic instructions for proteins. Most drugs in u...

Arranging Arrakis' syndicate

For its $75 million series B, Arrakis designed a syndicate that brought technical expertise and shared its ambitions to go public.

Good morning, tweeps. I have some news this morning -- NO REDACTIONS. First, the good ship Arrakis has refueled for its mission to discover new RNA-targeted small-molecule medicines. And I am down to merely one job. http://arrakistx.com/news/press-release

Good morning, tweeps. I have some news this morning -- NO REDACTIONS. First, the good ship Arrakis has refueled for its mission to discover new RNA-targeted small-molecule medicines. And I am down to ...

Series B round raises $75mm for Arrakis Therapeutics

Arrakis Therapeutics Inc. (developing RNA-targeted small molecule (rSM) therapies for cancer and other diseases) raised $75mm through its Series B round. VenBio Partners and Nextech Invest led (both a...

Arrakis Therapeutics has identified oral drug-like compounds that block RNA machinery needed to make #cancer-causing proteins. https://buff.ly/2PhTjbO 

Arrakis Therapeutics has identified oral drug-like compounds that block RNA machinery needed to make #cancer-causing proteins. https://buff.ly/2PhTjbO 

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [471 Associated PubMed Articles listed on BioPortfolio]

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

CRISPR: a promising tool for lipid physiology and therapeutics.

The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro.

In recent times, co-delivery of therapeutics has emerged as a promising strategy for treating dreadful diseases such as cancer.

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls.

Clinical Trials [179 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1340 Associated Companies listed on BioPortfolio]

Arrakis Therapeutics

Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. The company’s TRYST™ and PEARL-seqâ„...

Arrakis Servicios y Comunicaciones

Nil

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Arrakis Therapeutics" on BioPortfolio

We have published hundreds of Arrakis Therapeutics news stories on BioPortfolio along with dozens of Arrakis Therapeutics Clinical Trials and PubMed Articles about Arrakis Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Arrakis Therapeutics Companies in our database. You can also find out about relevant Arrakis Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record